DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

Protocol Title: A Prospective, Randomized Controlled Study of Venetoclax Plus 3-Day Decitabine (DEC3-VEN) Versus Venetoclax Plus "2+6" DA Versus "3+7" DA Regimen in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Objective: This is a prospective, open-label, randomized, multicenter, phase II trial designed to compare the efficacy and safety of three induction regimens-Venetoclax plus 3-day Decitabine (DEC3-VEN), Venetoclax plus "2+6" DA, and standard "3+7" DA-in adult patients with newly diagnosed, intensifiable AML. Study Design: The study employs a prospective, randomized,

Trial Details

NCT ID
NCT07712848
Phase
PHASE3
Sponsor
The Second Affiliated Hospital of Kunming Medical University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Arm A (VEN+"2+6"DA)
  • Arm B (DEC3-VEN)
  • Arm C ("3+7"DA)
Locations (sample)
  • Kunming, Yunnan, China|25.03889,102.71833

Key Eligibility Criteria

  • Subjects who are suitable for enrollment in this study must meet all of the following criteria:
  • Except for APL or carrying t(8) that meet the diagnostic criteria (WHO2022 criteria) of the World Health Organization; 21)/(RUNX1::RUNX1TI)、inv(16)…
  • Except for acute panmyeloproliferative disease with myelofibrosis and myeloid sarcoma, the World Health Organization AML classification is AML with…
  • Newly diagnosed AML patients with male or female, age greater than or equal to 16 years old and less than 65 years old, patients are considered sui…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →